<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04520321</url>
  </required_header>
  <id_info>
    <org_study_id>TTHX-001</org_study_id>
    <nct_id>NCT04520321</nct_id>
  </id_info>
  <brief_title>A Phase 1/ Phase 2 Study of TTHX1114(NM141)</brief_title>
  <acronym>INTREPID</acronym>
  <official_title>A Phase 1/ Phase 2 Study Evaluating the Safety and Efficacy of the Investigational New Drug TTHX1114(NM141) on the Regeneration of Corneal Endothelial Cells in Patients With Corneal Endothelial Dystrophies Following Intracameral Delivery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Trefoil Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Trefoil Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, multicenter, randomized, masked, vehicle-controlled, dose-escalation study that&#xD;
      includes a non-interventional observational sub-study in which subjects will undergo&#xD;
      (standard) ocular assessments&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multi-center, randomized, masked, vehicle-controlled, dose-escalation&#xD;
      study that will include an observational (no intervention) sub-study. Up to 71 eligible&#xD;
      subjects with moderate to severe corneal endothelial dystrophy (defined as Endothelial Cell&#xD;
      Density &lt; 2000 mm^2) in at least one eye will be enrolled and randomized in the main study.&#xD;
      The Observational Sub-study will enroll approximately 25 to 50 subjects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 19, 2020</start_date>
  <completion_date type="Actual">May 18, 2021</completion_date>
  <primary_completion_date type="Actual">April 23, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, Masked, Vehicle-controlled, Dose-escalation study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Corneal Endothelial Cell Count</measure>
    <time_frame>56 Days</time_frame>
    <description>Measured with Specular Microscopy</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Corneal Endothelial Dystrophy</condition>
  <condition>Fuchs Endothelial Corneal Dystrophy</condition>
  <condition>Pseudophakic Bullous Keratopathy</condition>
  <condition>Endothelial Dysfunction</condition>
  <arm_group>
    <arm_group_label>Vehicle (placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo weekly x 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TTHX1114(NM141) low-dose weekly x 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mid-dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TTHX1114(NM141) mid-dose weekly x 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TTHX1114(NM141) high-dose weekly x 4</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TTHX1114(NM141)</intervention_name>
    <description>engineered FGF-1 delivered intracamerally</description>
    <arm_group_label>High-dose</arm_group_label>
    <arm_group_label>Low dose</arm_group_label>
    <arm_group_label>Mid-dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Vehicle (placebo)</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Vehicle (placebo)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Fuchs Endothelial Corneal Dystrophy, pseudophakic bullous keratopathy, or endothelial&#xD;
             dysfunction/ insufficiency due to surgical intervention diagnosed more than 6 months&#xD;
             prior to Study Day 0&#xD;
&#xD;
          -  Central endothelial cell count of &lt; 2000 mm^2 in at least one eye as determined by the&#xD;
             central reading facility&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Conditions that would impair examination of the anterior chamber structure&#xD;
&#xD;
          -  Documented repeated elevated intra ocular pressure (in either eye)&#xD;
&#xD;
          -  Corneal transplant (in either eye)&#xD;
&#xD;
          -  Posterior Polymorphous Corneal Dystrophy (PPCD)&#xD;
&#xD;
          -  History of uveitis or herpetic keratitis&#xD;
&#xD;
          -  Cataract surgery within the past 3 months&#xD;
&#xD;
          -  Refractive surgery (in the Study Eye)&#xD;
&#xD;
          -  Anterior Chamber IOL placement (in the Study Eye)&#xD;
&#xD;
          -  Active extra-ocular inflammation from any non-infectious or infectious cause within&#xD;
             the past 6 months&#xD;
&#xD;
          -  Expected or planned ocular surgery within the next 3 months&#xD;
&#xD;
          -  Use of cytotoxic chemotherapy within the last 1 month&#xD;
&#xD;
          -  Treatment with a rho kinase inhibitor within the last 3 months&#xD;
&#xD;
          -  Use of cyclosporine ophthalmic emulsion or lifitegrast ophthalmic solution in the last&#xD;
             30 days&#xD;
&#xD;
          -  Systemic or ophthalmic corticosteroid use in the 30 days prior to Study Day 0 unless&#xD;
             approved by the Medical Monitor&#xD;
&#xD;
          -  History of significant allergy, hypersensitivity, or intolerance to any drug compound,&#xD;
             food, or other substance&#xD;
&#xD;
          -  Unwilling to use birth control&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas M Tremblay, RN BSN</last_name>
    <role>Study Director</role>
    <affiliation>Trefoil Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>North Bay Eye Associates, Inc.</name>
      <address>
        <city>Petaluma</city>
        <state>California</state>
        <zip>94954</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Levenson Eye Associates, Inc</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chicago Corneal Consultants</name>
      <address>
        <city>Hoffman Estates</city>
        <state>Illinois</state>
        <zip>60169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Price Vision Group</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tauber Eye Center</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vance Thompson Vision - Omaha</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68137</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alterman, Modi and Wolter</name>
      <address>
        <city>Poughkeepsie</city>
        <state>New York</state>
        <zip>12603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vance Thompson Vision - Sioux Falls</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>August 14, 2020</study_first_submitted>
  <study_first_submitted_qc>August 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2020</study_first_posted>
  <last_update_submitted>May 25, 2021</last_update_submitted>
  <last_update_submitted_qc>May 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Corneal Dystrophies, Hereditary</mesh_term>
    <mesh_term>Iridocorneal Endothelial Syndrome</mesh_term>
    <mesh_term>Fuchs' Endothelial Dystrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

